Study the Level of Interleukin -18 Binding Protein Alpha in Iraqi Arab female Patients with Diabetes Mellitus Type II
Keywords:IL-18Binding Protein alpha, Diabetes mellitus type2
AbstractDiabetes mellitus consider as inflammatory disease associated with many inflammatory factors for that the present study aims to investigate the concentration of IL-18 binding protein alpha with classical risk factors to study their role in Iraqi female patients with diabetes mellitus type2. The study included 60 female patients newly diagnosed with type 2 DM and 28 healthy individuals. The patients mean age was (47.48Â±1.08) while control mean age was (39.46Â±1.86). Laboratory tests were include detection of IL18BPa in serum by ELISA kits, chemical parameters which included Fasting blood glucose, Glycosylated haemoglobin Â and Lipid profile using enzymatic and colorimetric methods, besides anthropometric parameters includes central obesity andÂ body mass index. The present study showed a significant increasing in the serum level of IL-18binding protein alpha between DM type 2 patients and control. Fasting blood glucose, Glycosylated haemoglubin, total Cholesterol, Triglyceride, Low Density Lipoprotein, Very Low Density Lipoprotein and Atherogenic index showed significant increasing levels while a significant decreasing level of high density lipoprotein in sera of patients group compared to control group was observed also the mean of CO and BMI were non significant increased in patients group compared to control group. In conclusion, present study indicates that IL-18 binding protein alpha is an independent risk factor for diabetes mellitus type 2 in Iraqi Arab females. This result supported by the absence of significant correlation among IL-18 binding protein alpha and all others classical risk factors. While the increased level of IL-18 binding protein alpha associated with duration of disease and increased age over than fifty years old for patients and healthy females .Further studies are needed to understanding the relationship among present different factors.
-Wild S.Roglic G,Green A,et al. ?(2004) Global prevalence of diabetes:estimates for the year 2000 and projections for 2030.diabetes care 27:1047-1053.
- American Diabetes Association; (2008); Diagnosis and classification of Diabetes mellitus; Diabetes Care; 31 (suppl.1): S55- 60.
- Romaol Roth J (2008) Genetic and environmental interactions in obesity and type 2 diabetes.J Am Diet Assoc 108:S24-28.
- Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378:88 â€“91, 1995.
- Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53â€“72, 2001.
- Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999;10:127â€“136
- Kim, S. H., M. Eisenstein, L. Reznikov, G. Fantuzzi, D. Novick, M. Rubinstein, and C. A. Dinarello. 2000. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA
- Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 1999;36:67â€“72
-Wang, M.; Tan ,J.; Wang.Y.; Meldrum, K. K.; Denarello, C.A.; Meldrum,D. R.;(2009) IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction. Indiana University School of Medicine, Indianapolis, IN, 46202;
- Agha, Z .K.A. (2013). A Thesis "Immunological and Genetical study for Iraqi patients with Type 2 Diabetes Mellitus". College of Science for women . Baghdad U
- Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB. Circulating IL-18
and the risk of type 2 diabetes in women. Diabetologia 2009;52:2101â€“2108
- Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the
development of type 2 diabetes: results fromtheMONICA/KORA Augsburg Study,
-2002. Diabetes 2005;54:2932â€“2938
- Fantuzzi G, et al. (2003) Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J Leukoc Biol 74:889â€“896.
- Ali ,R .M.K.(2013) .A thesis "Study the association between ABO/Rh Blood groups and Endothelial inflammatory parameters in Iraqi Arab females with Diabetes Mellitus Type 2" .College of Science for women .Baghdad U.
- Kumar, S., Mukherjee, S., Mukhopadhyay, P. 2008. Prevalence of diabetes and impaired fasting glucose in a selected population with special reference to influence of family history and anthropometric measurements â€“ The Kolkata policeman study. JAPI, 56: 841-844.
- Daousi, C., Casson, I.F., Gill, G.V. 2006. Prevalence of obesity in type 2 diabetes patients in secondary care: association with cardiovascular risk factors. Postgrad. Med. J. 82: 280-284.
- Chan JM, Stampfer MJ, Ribb EB et al. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in man. Diabetes Care 1994;17:961-9.
- Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
- Stumvoll M, Goldstein B, van Haeften T. Type 2 diabetes: principles of
pathogenesis and therapy. Lancet. 2005;365:1333â€“1346
- American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S83â€“S86, 2003a
- Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density liÂ¬poprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009;119:2103-11.
- Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
- Lumeng C, Maillard I, Saltiel A. T-ing up inflammation in fat. Nat Med 2009; 15: 846-7.
-Shih,L.Y.; Ho,T.K.; Taso,H.C.; Chang,H.Y.; Shian,Y.M.; Huang,N.C.;Yang,C.S.; (2013) Role of Cyotkines in Metabolism and Type 2 Diabetes Mellitus. International Journal of Biomedical Laboratory Science (IJBLS) 2013 Vo1. 2, No. 1:1-6
- Dinarello,A.C.; Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis 2000; 59 (suppl I): i17â€“i20) .
How to Cite
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.